

# STEP THERAPY POLICY

**POLICY:** Topical Corticosteroids Step Therapy Policy

**REVIEW DATE:** 05/07/2025

Note: This list is not all-inclusive.

Product (Example Brand Name[s])	Strength	Topical Formulation		
Alclometasone dipropionate	0.05%	cream, ointment		
Amcinonide	0.1%	cream, ointment		
Betamethasone dipropionate, augmented	0.05%	cream, gel, lotion, ointment		
(Diprolene®)		cream, ger, lotton, omtiment		
Betamethasone dipropionate (Diprolene®, Sernivo™ Spray)	0.05%	cream, lotion, ointment, spray		
Betamethasone valerate (Luxiq®)	0.1%	cream, lotion, ointment		
	0.12%	foam		
Clobetasol propionate (Clobex®, Clodan®,	0.025%	cream		
Impeklo <sup>™</sup> , Impoyz <sup>™</sup> , Olux <sup>®</sup> , Olux-E <sup>®</sup> ,	0.05%	cream, foam, gel, lotion, ointment,		
Temovate® [brand obsolete 2024])		shampoo, solution, spray		
Clocortolone pivalate (Cloderm® [brand obsolete 2023])	0.1%	cream		
Desonide (DesOwen®, Tridesilon™ [brand obsolete 2023], Verdeso®)	0.05%	cream, foam, gel, lotion, ointment		
Desoximetasone (Topicort®)	0.05%	cream, gel, ointment		
	0.25%	cream, ointment, spray		
Diflorasone diacetate (Apexicon E®)	0.05%	cream, ointment		
Fluocinolone acetonide (Capex®, Derma-	0.01%	cream, body oil, scalp oil, solution		
Smoothe/FS®, Synalar®)	0.025%	cream, ointment		
Fluocinonide (Vanos®)	0.05%	cream, gel, ointment, solution		
	0.1%	cream		
Flurandrenolide (Cordran® [brand obsolete	0.05%	cream, lotion, ointment		
2025])	4 mcg/cm <sup>2</sup>	tape		
Fluticasone propionate (Beser <sup>™</sup> )	0.005%	ointment		
	0.05%	cream, lotion		
Halcinonide (Halog®)	0.1%	cream, ointment, solution		
Halobetasol propionate (Bryhali <sup>™</sup> ,	0.01%	lotion		
Lexette <sup>™</sup> , Ultravate <sup>®</sup> )	0.05%	cream, foam, ointment		
Halobetasol propionate and tazarotene (Duobrii <sup>™</sup> )	0.01%/0.045 %	lotion		
Hydrocortisone acetate (Ala-Scalp® HP,	0.5%	cream, ointment		
Scalacort <sup>™</sup> DK Kit, Texacort®)	1%	cream, lotion, ointment, solution		
	2%	lotion		
	2.5%	cream, lotion, ointment		
Hydrocortisone butyrate (Locoid®)	0.1%	cream, lotion, ointment, solution		
Hydrocortisone-pramoxine (Analpram HC®,	1%/1%	cream, foam		
Epifoam®; Pramosone®, Proctofoam® HC)	2.5%/1%	cream, lotion		
Hydrocortisone probutate (Pandel®)	0.1%	cream		
Hydrocortisone valerate	0.2%	cream, ointment		
Mometasone furoate	0.1%	cream, lotion, ointment, solution		
Prednicarbate	0.1%	cream, ointment		
Triamcinolone acetonide (Kenalog® Aerosol 0.025%		cream, lotion, ointment		
Spray, Trianex®, Triderm™)	0.05%	ointment		
	0.1%	cream, lotion, ointment, paste		

0.147 mg/g	spray
0.5%	cream, ointment

#### INSTRUCTIONS FOR USE

The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer's particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer's benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer's benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Each coverage request should be reviewed on its own merits. Medical directors are expected to exercise clinical judgment where appropriate and have discretion in making individual coverage determinations. Where coverage for care or services does not depend on specific circumstances, reimbursement will only be provided if a requested service(s) is submitted in accordance with the relevant criteria outlined in the applicable Coverage Policy, including covered diagnosis and/or procedure code(s). Reimbursement is not allowed for services when billed for conditions or diagnoses that are not covered under this Coverage Policy (see "Coding Information" below). When billing, providers must use the most appropriate codes as of the effective date of the submission. Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

# Cigna National Formulary Coverage:

#### **OVERVIEW**

Topical corticosteroids are, in general, indicated for symptomatic relief of inflammation and/or pruritus associated with acute and chronic corticosteroid-responsive skin disorders (dermatoses).<sup>1</sup>

Topical corticosteroids are adrenocorticosteroid derivatives that possess antiinflammatory, antipruritic, and vasoconstrictive properties.<sup>1</sup> These products are thought to depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid. Skin diseases that are responsive to topical corticosteroids usually have an inflammatory, hyperproliferative, and/or immunologic component (Table 1).

Table 1. Conditions Treated with Topical Corticosteroids.<sup>2</sup>

rable 1: conditions reduce with replear conticosterolas.				
High-potency steroids	Medium potency steroids	Low potency steroids		
(Groups I to II)	(Groups III, IV and V)	(Groups VI and VII)		
Alopecia areata	Anal inflammation (severe)	Dermatitis (diaper)		
Atopic dermatitis (resistant)	Asteatotic eczema	Dermatitis (eyelids)		
Bullous pemphigoid	Atopic dermatitis	Dermatitis (face)		
Discoid lupus	Dermatitis (severe)	Intertrigo		
Dyshidrotic eczema	Infantile acropustulosis	Perianal inflammation		
Hyperkeratotic eczema	Intertrigo (severe short term)	Phimosis		
Labial adhesion	Lichen sclerosus (vulva)			

High-potency steroids	Medium potency steroids	Low potency steroids
(Groups I to II)	(Groups III, IV and V)	(Groups VI and VII)
Lichen planus Lichen sclerosus (skin) Lichen simplex chronicus Melasma Nummular eczema Poison ivy (severe) Psoriasis Vitiligo	Nummular eczema Scabies (after scabicide) Seborrheic dermatitis Stasis dermatitis	

Topical corticosteroids are incorporated into a vehicle appropriate for application to the skin and external mucous membranes. Ointments are more occlusive and are generally preferred for dry scaly lesions.<sup>1</sup> Creams are generally preferred on oozing lesions or in intertriginous areas where a less occlusive preparation may be beneficial. Additionally, patients may prefer creams for aesthetic reasons although their water content makes them more drying than ointments. Gels, aerosols, lotions, and solutions are easier to apply on hairy areas.

### **POLICY STATEMENT**

This program has been developed to encourage the use of <u>two</u> prescription Step 1a Products prior to the use of a Step 2a Product (Duobrii is not included); or the use of one prescription Step 1b Product prior to the use of Duobrii (Step 2b). If the Step Therapy rule is not met for a Step 2 Product (a or b) at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

### **Step 1a/2a**

### **Step 1a Generic Topical Corticosteroid Products:**

Note: This is not an inclusive list.

- Alclometasone 0.05% ointment/cream
- Betamethasone dipropionate 0.05% lotion/ cream/ointment
- Betamethasone dipropionate, augmented 0.05% cream/ointment/lotion
- Betamethasone valerate 0.1% cream/lotion/ointment
- Clobetasol propionate 0.05% cream/emollient cream/gel/ointment/solution
- Desonide 0.05% cream/ointment
- Fluocinolone acetonide 0.01% cream/solution
- Fluocinolone acetonide 0.025% cream/ointment
- Fluocinolone acetonide 0.01% topical oil

- Halobetasol propionate 0.05% cream/ointment
- Hydrocortisone 2% lotion
- Hydrocortisone 1% cream/lotion/ointment/ solution
- Hydrocortisone 2.5% cream/lotion/ointment
- Hydrocortisone butyrate 0.1% cream/ emollient cream
- Hydrocortisone valerate 0.2% cream/ointment
- Mometasone furoate 0.1% cream/solution/ ointment
- Prednicarbate 0.1% cream/ointment
- Triamcinolone acetonide 0.025% cream/ lotion/ointment
- Triamcinolone acetonide 0.1% cream/lotion/ ointment

- Fluocinonide 0.05% cream/emollient cream/gel/ ointment/solution
- Fluticasone propionate 0.05% cream
- Fluticasone propionate 0.005% ointment

 Triamcinolone acetonide 0.5% cream/ointment

## **Step 2a Topical Corticosteroid Products:**

Note: This is not an inclusive list.

- Ala-Scalp HP
- Amcinonide 0.1% cream/lotion/ointment
- Analpram HC 2.5%/1% cream, lotion
- Aqua Glycolic HC
- Apexicon E 0.05% cream
- Beser 0.05% lotion (branded generic product)
- Betamethasone valerate 0.12% foam
- Bryhali 0.01% lotion
- Capex 0.01% topical shampoo
- Clobetasol propionate 0.05% foam/shampoo/ spray/lotion
- Clobetasol propionate 0.025% cream (authorized generic of Impoyz)
- Clobex 0.05% shampoo
- Clobex 0.05% spray
- Clobex 0.05% topical lotion
- Clodan 0.05% kit
- Cloderm 0.1% cream
- Clocortolone pivalate 0.1% cream
- Cordran 0.05% lotion/ointment
- Cordran SP 0.05% cream
- Cordran 4 mcg/sq cm tape
- Cutivate 0.05% lotion/cream
- Derma-Smoothe/FS Scalp Oil
- Desonide 0.05% gel and lotion
- Desonate 0.05% gel
- Desowen 0.05% cream kit
- Desowen 0.05% lotion kit
- Desoximetasone cream/gel/ointment

 Desoximetasone 0.25% cream/ointment

- Diflorasone diacetate 0.05% cream/ointment
- Diprolene 0.05% ointment/lotion
- Diprolene AF 0.05% creamElocon 0.1% ointment/cream/solution
- Epifoam

- Hydrocortisone butyrate 0.1% lotion/ointment/ solution
- Hydrocortisone-pramoxine 2.5%-1% cream
- Impeklo lotion
- Impoyz 0.025% cream
- Kenalog Aerosol Spray
- Lexette 0.05% foam
- Locoid Lipocream
- Locoid 0.1% lotion/cream/ointment/solution
- Luxiq 0.12% foam
- Olux 0.05% foam
- Olux-E 0.05% foam
- Pandel 0.1% cream
- Pramosone 1%/1% lotion
- Pramosone 2.5%/1% cream, lotion
- Proctofoam HC 1%/1%
- Scalacort DK Kit
- Sernivo 0.05% spray
- Synalar 0.025% cream/ointment
- Synalar 0.01% solution
- Synalar TS Kit
- Temovate 0.05% cream/ointment
- Texacort 2.5% solution
- Topicort 0.05% ointment/cream/gel
- Topicort 0.25% ointment/cream
- Topicort Spray 0.25%
- Triamcinolone acetonide 0.05% ointment Triamcinolone acetonide aerosol spray
- Trianex 0.05% ointment (branded generic product)
- Triderm 0.5% cream (branded generic product)
- Tridesilon cream 0.05%
- Ultravate 0.05% cream/lotion/ointment
- Ultravate X 0.05%-10% combination pack

0.05%

- Fluocinonide 0.1% cream
- Flurandrenolide 0.05% cream/lotion/ointment
- Fluticasone propionate 0.05% lotion
- Halcinonide 0.1% cream
- Halobetasol propionate 0.05% foam
- Halog 0.1% cream
- Halog 0.1% ointment

- Vanos 0.1% cream
- Verdeso 0.5% foam

### Step 1b/2b (Duobrii)

### **Step 1b Generic Topical Corticosteroid Products:**

Note: This is not an inclusive list.

- Alclometasone 0.05% ointment/cream
- Betamethasone dipropionate 0.05% lotion/ cream/ointment
- Betamethasone dipropionate, augmented 0.05% cream/ointment/lotion
- Betamethasone valerate 0.1% cream/lotion/ointment
- Clobetasol propionate 0.05% cream/emollient cream/gel/ointment/solution
- Desonide 0.05% cream/ointment
- Fluocinolone acetonide 0.01% cream/solution
- Fluocinolone acetonide 0.025% cream/ointment
- Fluocinolone acetonide 0.01% topical oil
- Fluocinonide 0.05% cream/emollient cream/gel/ ointment/solution
- Fluticasone propionate 0.05% cream
- Fluticasone propionate 0.005% ointment

- Halobetasol propionate 0.05% cream/ointment
- Hydrocortisone 2% lotion
- Hydrocortisone 1% cream/lotion/ointment/ solution
- Hydrocortisone 2.5% cream/lotion/ointment
- Hydrocortisone butyrate 0.1% cream/ emollient cream
- Hydrocortisone valerate 0.2% cream/ointment
- Mometasone furoate 0.1% cream/solution/ ointment
- Prednicarbate 0.1% cream/ointment
- Triamcinolone acetonide 0.025% cream/ lotion/ointment
- Triamcinolone acetonide 0.1% cream/lotion/ ointment
- Triamcinolone acetonide 0.5% cream/ointment

### **Step 2b Topical Corticosteroid Product:**

Duobrii

Topical Corticosteroids Step Therapy Policy product(s) is(are) covered as medically necessary when the following step therapy criteria is(are) met. Any other exception is considered not medically necessary.

#### **CRITERIA**

## **Step 2a Topical Corticosteroid Products**

**1.** If the patient has tried two prescription Step 1a Products for the *current* condition, approve a Step 2a Product.

<u>Note</u>: Products with the same chemical entity and same strength should <u>not</u> be considered as separate products.

# **Step 2b Topical Corticosteroid Product (Duobrii)**

**1.** If the patient has tried one prescription Step 1b Product for the *current* condition, approve Duobrii.

#### REFERENCES

- Facts and Comparisons® eAnswers. Wolters Kluver; 2024. Available at: <a href="http://fco.factsandcomparisons.com/lco/action/home">http://fco.factsandcomparisons.com/lco/action/home</a>. Accessed on May 2, 2025. Search terms: topical corticosteroids.
- 2. Stacey SK, McEleney M. Topical corticosteroids: choice and application. *Am Fam Physician*. 2021 Mar 15;103(6):337-343

#### **HISTORY**

1121 <b>0</b> K1				
Type of Revision	Summary of Changes	Review Date		
Early Annual Revision	<b>Halobetasol propionate 0.05% foam</b> : The generic of Lexette (halobetasol propionate 0.05% foam) was added to the Policy to Step 2a.	01/17/2024		
Early Annual Revision	<b>Step 2a Topical Corticosteroid Products</b> : The following Note was added "Products with the same chemical entity and same strength should <u>not</u> be considered as separate products."	11/06/2024		
Selected Revision	<b>Generic clocortolone pivalate 0.1% cream</b> : Moved from Step 1a to Step 2a.	03/05/2025		
Early Annual Revision	<b>Step 2a Topical Corticosteroid Products</b> : Clobetasol propionate 0.025% cream (authorized generic of Impoyz) was added to Step 2a. Nolix 0.05% cream/lotion (branded generic product) was removed as obsolete.	05/07/2025		

<sup>&</sup>quot;Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2025 The Cigna Group.